NCT07362056 Implementing Suicide Prevention Into Primary Care in Nepal
| NCT ID | NCT07362056 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yale University |
| Condition | Suicide |
| Study Type | INTERVENTIONAL |
| Enrollment | 147 participants |
| Start Date | 2025-11-15 |
| Primary Completion | 2027-07-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 147 participants in total. It began in 2025-11-15 with a primary completion date of 2027-07-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Suicide remains a major contributor to global mortality, with particularly high and persistent rates in low-resourced settings such as South Asia. In Nepal, ongoing integration of mental health services into primary care provides a critical opportunity to strengthen suicide risk assessment and management. Despite the scale-up of mhGAP training for primary care providers (PCPs), gaps remain in the systematic detection, referral, and follow-up of individuals at risk for suicide. There is an urgent need to enhance mhGAP implementation with strategies that address provider workload, stigma, and inequities within the health workforce. Using experience-based co-design principles and RE-AIM this study will assess the feasibility and acceptability of integrating an implementation strategy package to optimize mhGAP suicide prevention delivery in Nepal's decentralized primary healthcare system. This clinical trial leverages deep collaboration with a community advisory board of individuals with lived experience of suicide throughout the trials' design, delivery and analysis. This R34 will generate critical preliminary evidence on the feasibility, acceptability, and implementation of an integrated suicide prevention package within government primary care facilities in Nepal. The findings will inform the design and parameters of a future fully powered effectiveness trial, while aligning with Nepal's national suicide prevention strategy and advancing WHO and NIMH global mental health priorities.
Eligibility Criteria
Inclusion Criteria: Primary Care Providers * Health workers with a prescribing license employed in government health facilities in Bagmati Province. * Are between 21-65 years, per government health system criteria. * Participants will be required to have competency in Nepali, be actively engaged in care provision within their health facility Patients: * Patient lives in the study site * Is under the care of a PCP at a facility site. * Patient meets any level of suicide risk based on mhGAP 2.0 criteria. * Patients who have been treated for mental illness before or presently (expected in both groups). * Speaks Nepali. * Levels of Suicide Risk (as defined by mhGAP 2.0) Exclusion Criteria: Primary Care Providers * Healthcare workers without proper government credentials will be excluded. * Health workers who plan to migrate or who do not intend to stay in the study area for at least a year. Patients: * Patient requiring immediate hospitalization * Unable to consent as determined by the diminished capacity tool.
Contact & Investigator
Ashley K Hagaman, PhD, MPH
PRINCIPAL INVESTIGATOR
Yale School of Public Health
Frequently Asked Questions
Who can join the NCT07362056 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Suicide. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07362056 currently recruiting?
Yes, NCT07362056 is actively recruiting participants. Contact the research team at ashley.hagaman@yale.edu for enrollment information.
Where is the NCT07362056 trial being conducted?
This trial is being conducted at Dolakhā, Nepal.
Who is sponsoring the NCT07362056 clinical trial?
NCT07362056 is sponsored by Yale University. The principal investigator is Ashley K Hagaman, PhD, MPH at Yale School of Public Health. The trial plans to enroll 147 participants.